【摘要】 目的 探讨利拉鲁肽联合应用丹蒌片对冠心病合并2型糖尿病患者的干预作用.方法 将120例冠心病伴2型糖尿病患者随机分为利拉鲁肽组、丹蒌片组和联合用药组，每组40例.比较3组治疗前后总胆固醇(Total cholesterol, TC)、甘油三酯(Triglyeride, TG)、低密度脂蛋白(Low density lipoprotein, LDL)、高密度脂蛋白(High density lipoprotein, HDL)、肿瘤坏死因子-α(Tumor necrosis factor-α,TNF-α)、白细胞介素-6(Interleukin-6,IL-6)水平及颈动脉斑块变化情况.结果 3组治疗前上述指标比较差异均无统计学意义(P>0.05).与治疗前比较，治疗后丹蒌片组和利拉鲁肽组患者TC、TG、LDL-C、TNF-α、IL-6、颈动脉斑块直径以及IMT数值均有所下降(P<0.05),同时HDL-C水平较治疗前升高(P<0.05);利拉鲁肽和丹蒌片联合应用后，患者HDL-C水平高于单一用药组(P<0.05),其他指标均低于单一用药组(P<0.05).结论 利拉鲁肽与丹蒌片能够降低冠心病合并2型糖尿病患者的血脂水平，抑制促炎细胞因子的产生，进而减轻炎性细胞对心脏的损伤，稳定颈动脉斑块，从而抑制疾病发展，且联合用药强于单一用药，安全性较高.更多还原

【Abstract】 Objective To explore the effect of Liraglutide combined with Danlou tablet on coronary heart disease combined with type 2 diabetes.Method 120 patients with coronary heart disease complicated with type 2 diabetes were randomly divided into Liraglutide group, Danlou tablet group and combination group, 40 cases in each group.The levels of total cholesterol(TC),triglyceride(TG),low density lipoprotein(LDH) and high density lipoprotein(HDL),tumor necrosis factor-α(TNF-α),Interleukin-6(IL-6) and carotid plaque were compared before and after treatment among the three groups.Results There was no difference in the above indexes among the three groups before treatment(P>0.05).Compared with before treatment, TC, TG, LDL-C,TNF-α,IL-6,carotid plaque diameter and IMT were decreased in Danlou tablet group and Liraglutide group(P<0.05),and the level of HDL-C was increased(P<0.05).The level of HDL-C in combination with Liraglutide and Danlou tablet was higher than that in single drug group(P<0.05),and other indicators were lower than that in single drug group(P<0.05).Conclusion Liraglutide and Danlou tablet could reduce the blood lipid level, inhibit the production of proinflammatory factors, reduce inflammatory damage, stabilize carotid plaque and inhibit the development of coronary heart disease with type 2 diabetes.The combination of Liraglutide and Danlou tablet was better than single drug, and had higher safety.更多还原